Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash & Equivalents (2016 - 2025)

Fennec Pharmaceuticals filings provide 16 years of Cash & Equivalents readings, the most recent being $36.8 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 38.12% to $36.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.8 million, a 38.12% increase, with the full-year FY2025 number at $36.8 million, up 38.12% from a year prior.
  • Cash & Equivalents hit $36.8 million in Q4 2025 for Fennec Pharmaceuticals, up from $21.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $51.2 million in Q1 2024 to a low of $12.4 million in Q3 2023.
  • Median Cash & Equivalents over the past 5 years was $23.2 million (2022), compared with a mean of $25.1 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 58.33% in 2023 and later surged 285.74% in 2024.
  • Fennec Pharmaceuticals' Cash & Equivalents stood at $21.1 million in 2021, then grew by 12.67% to $23.8 million in 2022, then crashed by 44.19% to $13.3 million in 2023, then surged by 100.72% to $26.6 million in 2024, then soared by 38.12% to $36.8 million in 2025.
  • The last three reported values for Cash & Equivalents were $36.8 million (Q4 2025), $21.9 million (Q3 2025), and $18.7 million (Q2 2025) per Business Quant data.